Incanthera (AQSE:INC) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 28, 2026)


What is Incanthera Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Incanthera's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

AQSE:INC vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Incanthera's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incanthera Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Incanthera's Margin of Safety % (DCF FCF Based) falls into.


Incanthera Business Description

Address C/o Gateley Plc, 98 King Street, Manchester, GBR, M2 4WU
Incanthera PLC is clinical stage drug development. It specializes in dermatology and oncology therapeutics. The company has launched a skincare range called Skin + CELL, which addresses and enhances life quality through effective delivery of bioactive ingredients capable of energising the skin's natural repair and defence processes at the cellular level. It has one reportable segment, namely the development of dermatology and pharmaceutical products, within the United Kingdom and Switzerland.